Human IL-2 DTSet enzyme-linked immunoassay kit
| Specification | 96*5 Test；96T*15 Test |
|---|---|
| Standard Curve Range | 15.63 pg/ml-1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl |
| Type | Not Ready-to-Use |
| Test Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0153 | 0.0164 | 0.0159 | |
| 15.63 | 0.0908 | 0.0819 | 0.0864 | 0.0705 |
| 31.25 | 0.1504 | 0.1490 | 0.1497 | 0.1339 |
| 62.50 | 0.2953 | 0.2956 | 0.2955 | 0.2796 |
| 125.00 | 0.5887 | 0.5429 | 0.5658 | 0.5500 |
| 250.00 | 1.1280 | 1.0380 | 1.0830 | 1.0672 |
| 500.00 | 1.9580 | 1.7880 | 1.8730 | 1.8572 |
| 1000.00 | 3.1140 | 3.1170 | 3.1155 | 3.0997 |
Product Features
- Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
- Development protocols are provided to guide further assay optimization
- Assay can be customized to your specific needs
- Economical alternative to complete kits
Kit Content
- Capture Antibody
- Detection Antibody
- Recombinant Standard
- Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)
Other Reagents Required
DTSet Ancillary Reagent Kit (5 plates): containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and assay buffer.
- 96 well microplates: YOUKE Life, Catalog # DSEP01. Plate Sealers: YOUKE Life, Catalog # DSSF01.
- Coating Buffer: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4, 0.2 μm fi ltered . YOUKE Life, Catalog # DSCB01.
- Blocking Buffer: YOUKE Life, Catalog # DSBB01.
- Wash Buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4. YOUKE Life, Catalog # DSWB01.
- Assay Buffer: 0.5%BSA，0.05%Tween20，PBS Solution.YOUKE Life, Catalog # DSAB01
- Substrate Solution: Tetramethylbenzidine. YOUKE Life, Catalog # DSTS01.
- Stop Solution: 0.5mol/ml H2SO4. YOUKE Life, Catalog # DSSS01.
Product Data Sheet
Background: IL-2
Interleukin 2 (IL-2), also known as T cell growth factor (TCGF), is a 15-18 kDa variably glycosylated alpha -helical polypeptide that is a member of the Common gamma Chain ( gamma c) cytokine family. It exists as a monomer and has a notably short half-life (< 30 minutes). Human IL-2 is synthesized as a 153 amino acid (aa) precursor that contains a 20 aa signal sequence plus a 133 aa mature region. The mature region is alpha -helical in nature, and contains one utilized O-linked glycosylation site at Thr3 plus three cysteines, two of which form an intrachain disulfide bond that is essential for activity. Mature human IL-2 shares 73%, 66%, 78% and 97% aa identity with canine, rat, feline and rhesus monkey IL-2, respectively. Although human IL-2 shares only approximately 60% aa identity with the highly polymorphic mouse IL-2, human IL-2 is known to be active on mouse IL-2 responsive cells. Cells reported to secrete IL-2 include gamma δ T cells, activated conventional CD4+ and CD8+ T cells, neurons, microglia, and hematopoietic stem cells.
The receptor for IL-2 (IL-2 R) is composed of three subunits, the 55 kDa CD25/IL-2 R alpha chain, the 70 kDa IL-2 R beta chain, and the 65 kDa Common gamma Chain. IL-2 first binds to CD25, the binary complex then recruits IL-2 R beta and gamma c to form the quaternary signaling complex. In addition to IL-2, IL-2 R beta is used by IL-15 in its quaternary signaling complex. gamma c also serves as a signaling receptor for IL-4, -7, -9, -15, and -21.
In vitro studies have shown an important role for IL-2 in T cell activation and expansion. In vivo, IL-2 is critical for the development, maintenance and function of regulatory T cells (Treg) which provide protection against autoimmune disease. On the other hand, IL-2 can also promote autoimmune inflammation in target organs through its roles in regulating the expression of T cell trafficking genes, and production of Th2 cytokines. Within the CD8+ T cell subset, IL-2 is essential for optimal primary responses and differentiation into terminal effector cells. IL-2 also promotes the development of activated CD8+ T cells into memory cells.
